Welcome to our dedicated page for DIH Holdings US news (Ticker: DHAI), a resource for investors and traders seeking the latest updates and insights on DIH Holdings US stock.
DIH Holdings US (DHAI) specializes in advanced robotic rehabilitation systems that integrate virtual reality for clinical research and patient therapy. This page serves as the definitive source for official news and press releases related to the company’s technological advancements, strategic partnerships, and clinical milestones.
Investors and healthcare professionals will find timely updates on product innovations, research collaborations, and market expansion initiatives. Our curated collection includes earnings announcements, regulatory developments, and case studies demonstrating how DHAI’s devices improve motor function recovery through interactive therapy solutions.
All content undergoes rigorous verification to ensure accuracy and relevance. Bookmark this page to stay informed about breakthroughs in robotic rehabilitation technology and DHAI’s role in shaping modern healthcare infrastructure worldwide.
DIH (NASDAQ:DHAI) reported fiscal 2025 results for year ended March 31, 2025: revenue $62.9M (down 2.5% YoY), device revenue $49.7M, service revenue $12.0M (service +8.4%), and gross profit $32.2M (up 8.2%). Operating cash flow was negative $4.1M and cash on hand was $1.9M at March 31, 2025. Q4 revenue was $12.6M (down 34.7%), with EMEA distributor headwinds cited.
Key corporate actions after year end include issuing senior secured convertible debentures ($2.2M principal, $1.9M expected net proceeds), warrants for 8,888,888 shares at $0.25, a 1-for-25 reverse stock split effective October 17, 2025 (outstanding shares reduced to ~2.1M), and an equity line up to $22M with upfront fees of 2,500,000 shares plus a 2,500,000 pre-funded warrant.
DIH Holding US (NASDAQ: DHAI) announced a 1-for-25 reverse stock split of its Class A common stock, effective at market open on October 20, 2025. The split was approved by stockholders on September 25, 2025 with the final ratio set by the board on September 26, 2025. Post-split trading will continue under the existing ticker DHAI and the new CUSIP will be 23290B205. Outstanding shares will be converted with fractional shares rounded up to whole shares; no cash will be paid for fractional shares. Outstanding share count is expected to move from ~52,316,314 to ~2,092,652.
DIH Holding (NASDAQ:DHAI) has clarified its previous disclosure regarding a Nasdaq delisting notice. The company received notification on September 12, 2025 about its failure to comply with multiple Nasdaq listing requirements, including the Bid Price Rule and Reports Rule due to unfiled Form 10-Q and Form 10-K.
The company has requested a hearing before the Nasdaq Panel, which has temporarily stayed the stock suspension for 15 days. DIH will present its compliance plan at the hearing and seek an extension of up to 180 days for the MVLS and Bid Price Rules, and 360 days for the filing delinquency. However, there is no guarantee that the Panel will grant the extension or that DIH will achieve compliance within the given timeframe.
DIH Holding US (NASDAQ:DHAI) has received an additional delisting notice from Nasdaq on September 12, 2025, due to failing to meet the minimum bid price requirement of $1.00 per share. This follows a previous notice from March 11, 2025, which gave the company a 180-day compliance period that ended September 8, 2025.
The company has requested a hearing before the Nasdaq Hearing Panel, which has temporarily stayed the stock suspension for 15 days. DIH will present its compliance plan at the hearing and seek an extension, with the Panel having authority to grant up to 180 days from the staff's determination date for bid price compliance and 360 days for filing delinquency.
DIH Holding US (NASDAQ:DHAI), a provider of advanced robotic rehabilitation devices, has appointed Dr. Barrett Mooney to its Board of Directors. Dr. Mooney brings extensive experience in scaling complex manufacturing and technology businesses, with expertise in AI-driven solutions and public market transitions.
Dr. Mooney's background includes serving as CEO of a NYSE American-listed aerospace company, founding and selling HydroBio Inc. to The Climate Corporation, and leading AI implementation at CropIn Technology Solutions. He holds a Ph.D. in Engineering from the University of Florida.
With this appointment, DIH's Board now consists of seven members, including five independent directors, reinforcing the company's commitment to strong corporate governance.
DIH Holding US (NASDAQ:DHAI) has received a delisting notice from Nasdaq on September 2, 2025, after failing to meet the minimum market value requirement of $50 million for continued listing on the Nasdaq Global Market.
The company was initially notified of this deficiency on March 5, 2025, and was given a 180-day compliance period until September 1, 2025. DIH plans to request a hearing before the Nasdaq Hearing Panel, which will temporarily stay any delisting action. The Panel has the authority to grant DIH an extension of up to 180 days for market value compliance.
DIH Holding US (NASDAQ:DHAI) has received a deficiency notice from Nasdaq on August 26, 2025, due to failing to file its Q2 2025 Form 10-Q and FY 2025 Form 10-K. The company has until September 29, 2025 to submit a compliance plan to Nasdaq.
If Nasdaq accepts the plan, DIH could receive up to 180 days (until January 12, 2026) to regain compliance. The company is working with auditors to file the delinquent reports. Currently, there is no immediate impact on DHAI's Nasdaq listing or trading.
DIH Holding US (NASDAQ:DHAI), a global provider of advanced robotic rehabilitation devices, has appointed Scott R. Burell to its Board of Directors. Burell, currently CFO of AIVITA Biomedical, brings over two decades of healthcare finance experience and expertise in complex transactions.
As a seasoned executive, Burell has significant experience in public and private financing, corporate reorganizations, and M&A activities. He also serves on the Board of Microbot Medical (NASDAQ: MBOT) and previously led CombiMatrix Corporation through its acquisition by Invitae Corp. With his appointment, DIH's Board now consists of six members, including four independent directors.
DIH Holding US (NASDAQ:DHAI) has received a notice from Nasdaq on July 29, 2025, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 10-K for the period ended March 31, 2025.
The company has 60 calendar days to file the Annual Report or submit a compliance plan. If Nasdaq accepts the plan, DIH could receive up to 180 days from the original due date to regain compliance. While DIH is actively working with auditors to file the report, the notice currently has no immediate impact on the company's Nasdaq listing or stock trading.
DIH Holding US (NASDAQ:DHAI), a global provider of advanced robotic rehabilitation devices, has appointed Dennis Streppa to its Board of Directors and as Audit Committee Chair. Streppa brings significant healthcare industry experience, having served as a global Chief Operations Officer with expertise in both public and private healthcare companies.
His background includes driving M&A value at Cardinal Health, leading an $800M manufacturing P&L, and executing multi-million-dollar private equity deals. The appointment expands DIH's board to five members, with three being independent, strengthening the company's governance structure.
FAQ
What is the current stock price of DIH Holdings US (DHAI)?
What is the market cap of DIH Holdings US (DHAI)?
